Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study - 08/09/20
Funding sources: None. |
|
Conflicts of interest: Dr Vender has been a speaker, consultant, advisory board member, and investigator for AbbVie, Actelion, Amgen, Astellas, Celgene, Dermira, Eli Lilly, Galderma, Janssen Ortho, Leo, Merck, Novartis, Pfizer, Regeneron, and Takeda. Dr Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GSK, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon. Drs Georgakopoulos and Mufti have no conflicts of interest to declare. |
|
Reprints not available from the authors. |
Vol 83 - N° 4
P. 1212-1214 - octobre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.